Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Licenses Acquired - Additional Information (Detail)

v3.10.0.1

Licenses Acquired - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development in Process			$ 0.0
Mustang Therapeutics, Inc [Member] \| License and Maintenance [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cost, Maintenance				$ 0.1
Dana Farber License CK-301 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development in Process		$ 1.0		1.0
St Jude Childrens Research Hospital [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Other Fees	$ 1.0
Revenue Recognition Milestone Method Payments Due	$ 13.5
Caelum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development in Process		0.2	0.2	0.0	$ 0.2
Cyprium [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development in Process					0.1
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments For Research And Development Expenses		$ 1.5	$ 1.5	$ 0.0	$ 0.0

- Definition

The amount of cash outflow associated research and development expenses paid during the period.

+ References

No definition available.

+ Details

Name:	fbio_PaymentsForResearchAndDevelopmentExpenses
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The fact represents payment of revenue recognition milestone method payments due.

+ References

No definition available.

+ Details

Name:	fbio_RevenueRecognitionMilestoneMethodPaymentsDue
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=fbio_MustangTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=fbio_DanaFarberLicenseCK301Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=fbio_StJudeChildrensResearchHospitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_CaelumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_CypriumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fbio_HelocyteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: